Related Experiment Video
Updated: Jul 31, 2026
09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth
A Yu1, P Somasundar, A Balsubramaniam
1Department of Surgery, Robert C. Byrd Health Sciences Center, Morgantown, West Virginia 26506-9238, USA.
The Journal of Surgical Research
|June 19, 2002
Summary
Alpha-tocopherol succinate (ATS) and peptide YY (PYY) inhibit hormone-refractory prostate cancer growth. ATS reduces vascular endothelial growth factor (VEGF) production, while PYY increases it, an effect abolished by ATS in combination therapy.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Alpha-tocopherol succinate (ATS), a vitamin E form, induces apoptosis and inhibits hormone-refractory prostate cancer (PCa) growth.
- Peptide YY (PYY) exhibits anti-cancer properties and synergizes with ATS in inhibiting breast and pancreatic cancer.
- BA-129, a Y4 receptor agonist, shows growth inhibitory effects on pancreatic cancer.
Purpose of the Study:
- To investigate the effects of BA-129 and ATS on hormone-refractory prostate cancer growth.
- To evaluate the impact of BA-129 and ATS on vascular endothelial growth factor (VEGF) production in prostate cancer.
Main Methods:
- PC-3 human prostate cancer cells were treated with ATS, PYY, or BA-129 alone or in combination.
- Cell growth was assessed using MTT assay and hemocytometry (trypan blue exclusion).
- VEGF levels were quantified by ELISA; statistical significance was determined by ANOVA.
Main Results:
- Both ATS and PYY demonstrated significant growth inhibition in PC-3 cells.
- ATS treatment decreased VEGF production, whereas PYY treatment increased it.
- Combination therapy with ATS and BA-129 further reduced VEGF production.
Conclusions:
- PYY and ATS synergistically inhibit hormone-refractory prostate cancer growth.
- ATS inhibits VEGF production, while PYY augments it; ATS counteracts PYY's effect on VEGF.
- PYY plays a role in regulating prostate cancer growth and VEGF production.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...